Sanofi India Limited has informed the Exchange regarding Appointment of Ms. Sudipta Chakraborty as Executive Director of the company w.e.f. March 01, 2026.
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts less than Nifty Microcap 250 and 3.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanofi India's board approved audited results for the financial year ended December 31, 2025. Revenue from operations fell to ₹18,374 crore from ₹20,132 crore in FY24, impacted by lower export sales (down ₹1,481 million) due to the anticipated end of a contract with Zentiva. Profit before tax from continuing operations rose slightly to ₹4,447 crore versus ₹4,314 crore, while net profit from continuing operations grew to ₹3,267 crore (EPS of ₹141.85 vs ₹136.21). The board recommended a final dividend of ₹48 per share, taking total FY25 dividend to ₹123 per share (including ₹75 interim). On the board, Mr. Rodolfo Hrosz resigned as Non-Executive Director effective February 28, 2026 due to other commitments. Ms. Sudipta Chakraborty (ex-Aditya Birla Group legal head) was appointed as Whole-time Director and KMP for 3 years from March 1, 2026, and Mrs. Rajani Kesari (former CFO of Nayara Energy) was appointed as Independent Director for 5 years from April 1, 2026. Statutory auditors Price Waterhouse issued an unmodified opinion.
Shareholders get a healthy total dividend of ₹123 per share, though the topline decline from export losses is a concern. The new director appointments strengthen governance and legal expertise, but the export contract loss with Zentiva is a near-term revenue headwind worth monitoring.